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Abstract: Esophageal cancer is one of the most lethal cancers worldwide and its incidence is 
increasing at an alarming rate. Despite advances in surgical techniques and combined multi-
modality therapy, the survival rate of esophageal cancer remains poor. Clearly, the time is ripe 
for introducing novel strategies such as targeted therapies to improve treatment outcome. The 
significance of angiogenesis and angiogenic factors in the progression and aggressiveness of 
esophageal cancer is well documented. However, although increasing numbers of antiangiogenic 
agents designed to inhibit angiogenesis through multiple mechanisms have been developed in 
the past few decades, and some of them have shown promising results in preclinical and clinical 
studies, there is as yet no antiangiogenic agent approved for esophageal cancer. This review 
provides a summary of angiogenesis and vasculogenesis, the molecular mechanisms that regulate 
these processes, and the strategies for targeting angiogenesis in tumors. We will also present 
the rationale and challenges of antiangiogenic therapy, and the antiangiogenic agents that have 
been tested in preclinical studies or clinical trials for esophageal cancer. With further research 
bringing a deeper understanding of the molecular mechanisms involved in angiogenesis, and 
as new angiogenesis-targeting agents continue to evolve, there are reasons to be optimistic that 
targeting angiogenesis may bring new opportunities to cure this highly lethal disease.
Keywords: esophageal cancer, angiogenesis, vascular endothelial growth factor, targeted 
therapies
Introduction
Esophageal cancer is the sixth most lethal cancer worldwide and its incidence is on the 
rise.1,2 Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma 
(EAC) are the two predominant subtypes of esophageal cancer.3 ESCC develops from 
epithelial cells and can occur anywhere along the esophagus, whereas EAC arises 
from glandular cells in the lower third of the esophagus, which replace an area of 
squamous cells. For tumors that occur in the gastroesophageal junction (GEJ), those 
in which the epicenter is within 5 cm of the GEJ and also extends into the esophagus, 
are also classified by the International Union Against Cancer as esophageal cancer.4 
Worldwide, ∼90% of the new cases of esophageal cancer are ESCC and two-thirds 
of the cases occur in Asia. However, the past 30 years have witnessed a significant 
increase in the incidence of esophageal cancer in the United States and Europe. 
According to the latest data published by the American Cancer Society, there were 
18,170 new cases and 15,450 deaths of esophageal cancer in the US in 2014. Smoking, 
alcohol consumption, hot drinks, and poor diet are regarded as the main risk factors 
for squamous cell-type esophageal cancer, whereas the most common causes of the 
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adenocarcinoma-type esophageal cancer are gastroesopha-
geal reflux disease, Barrett’s esophagus (BE), and obesity.3 
The fact that most esophageal cancer patients have advanced 
disease at the time of diagnosis makes surgery futile in the 
majority of cases. For the patients deemed inoperable, the 
combination of chemotherapy and radiotherapy is becoming 
more and more important. Despite the great improvements 
in diagnosis, surgical resection, and neoadjuvant/adjuvant 
chemoradiotherapy in the past few decades, the 5-year 
survival rate of esophageal cancer rarely exceeds 30%.5 
 Therefore, new treatment strategies for this highly lethal 
disease are urgently needed.
Angiogenesis and vasculogenesis
The term “angiogenesis” was firstly proposed in 1935 by 
Hertig6 to describe the physiological process through which 
new blood vessels form from pre-existing vessels in the 
placenta of pregnant monkeys. Angiogenesis occurs during 
development, wound healing, pregnancy, and other physi-
ological processes. However, angiogenesis is also an essential 
step in the conversion of a tumor from benign to malignant 
and metastatic phenotypes. Tumor growth is a complex and 
multistep process involving recruitment of the neighboring 
blood vessels or endothelial cells to deliver oxygen and nutri-
ents into the tumor microenvironment to construct a favorable 
environment for tumor growth. The tumor microenvironment 
is a complex system.7 Compelling evidence has shown that 
besides cancer cells, endothelial progenitor cells, pericytes, 
and fibroblasts also significantly contribute to the develop-
ment of tumors.8–10
The concept that tumor growth mimics embryonic 
development is not new.11 It has become increasingly evi-
dent that a tumor can effectively hijack and exploit various 
physiological functions and revert quiescent cell types to 
their embryonic state of proliferation and differentiation. 
In the 1971 issue of the New England Journal of  Medicine, 
Judah Folkman launched the idea that all tumors are 
 angiogenesis-dependent.12 In 1984, the first tumor angiogenic 
factor, basic fibroblast growth factor (bFGF or FGF-2), was 
characterized by Shing et al13 from a chondrosarcoma. This 
finding further supported the notion that tumors can induce 
neovascularization by secreting angiogenic factors. In sub-
sequent decades, an increasing number of angiogenic factors 
with distinct functions in the regulation of vessel growth and 
vascular remodeling, including matrix metalloproteinase 
(MMPs)14 and angiopoietins,15 were identified. Another key 
concept termed “angiogenic switch” refers to the moment 
at which a tumor overwhelms the delicate balance between 
pro- and antiangiogenic factors, and begins to express high 
levels of proangiogenic factors, resulting in the transition 
from a dormant state to an outgrowing vascularized tumor 
and eventually to malignancies.16 Now, angiogenesis is gain-
ing more and more recognition and is regarded as one of the 
important hallmarks of cancer.17
Distinct from “angiogenesis”, which refers to blood 
vessels sprouting from already established vasculature, 
the term “vasculogenesis” describes the formation of new 
blood vessels when there are no pre-existing ones. In 2001, 
Lyden et al18 demonstrated that impaired recruitment of 
bone marrow-derived endothelial and hematopoietic pre-
cursor cells could effectively block tumor angiogenesis 
and growth. For the first time, they proposed that tumor 
growth is not only angiogenesis-dependent, but also 
 vasculogenesis-dependent.18 Furthermore, the study by Kioi 
et al19 documented the importance of blocking vasculogenesis 
in the prevention of tumor recurrence. The growth factors 
secreted by tumor cells, such as vascular endothelial growth 
factor (VEGF) and transforming growth factor beta (TGF-β), 
can augment mobilization and recruitment of bone marrow-
derived cells (BMDCs) which, in turn, facilitate tumor 
neovascularization.20–22 Several subpopulations of BMDCs, 
for example, CD11b+/Gr1+ bone marrow-derived myeloid 
cells,23 Tie2+-expressing monocytes,24 and VEGF receptor 
1-positive (VEGFR1+) bone marrow-derived hematopoi-
etic progenitor cells,21 have been observed to significantly 
contribute to tumor growth. Pharmacological manipulation 
by using antiangiogenic drugs or genetic regulation can 
retard mobilization of the various BMDCs, and thus reduce 
the angiogenic response and inhibit tumor progression. 
Our recent preclinical study showed that simply targeting 
nontumor cells that express VEGFR1 and VEGFR2 using 
neutralizing antibodies is sufficient to significantly suppress 
tumor growth and angiogenesis in immunodeficient mice 
xenografted with ESCC cells.25 However, our understanding 
of the formation of tumor vessels by vasculogenesis is still in 
its infancy. The respective roles of selective subpopulations of 
BMDCs and how they are integrated into the growing tumor 
remain to be further elucidated.
VEGF and molecular mechanisms 
of angiogenesis
VEGF was discovered in 1983 and was first identified as an 
angiogenic factor in 1989.26 VEGF belongs to the platelet-
derived growth factor (PDGF) family and it is a collective 
name for a broad range of proteins, including VEGF-A (also 
referred to as VEGF because it was the first VEGF isoform 
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to be discovered), VEGF-B, VEGF-C, and VEGF-D. The 
normal function of VEGF is to create new blood vessels 
during embryonic development or after injury, whereas the 
overexpression of VEGF is often related to disease, such as 
cancer.27 Emerging evidence demonstrated the significant 
association between VEGF expression and cancer progres-
sion and prognosis in a variety of gastrointestinal malignan-
cies, including esophageal,28,29 gastric,30 colon,31 and many 
other cancer types. VEGF can be secreted by tumor or stromal 
cells to exert functions in an autocrine or paracrine manner. 
VEGF plays a predominant role in angiogenesis by binding 
to VEGF receptors (VEGFR1, VEGFR2, and VEGFR3), 
which are kinase insert domain-containing receptors, or to 
neuropilins (such as NRP1 and NRP2) which are a class of 
nontyrosine kinase receptors.32 VEGF receptors (VEGFRs) 
are expressed in normal tissues as well as in tumor cells. 
VEGFRs have been reported to play important roles in the 
control of cell proliferation and differentiation. VEGFR1 is 
the only known receptor for placental growth factor (PlGF) 
and VEGF-B, and it can be expressed as a soluble variant. 
Increasing evidence shows that VEGFR1 may be a promising 
therapeutic target for the treatment of cancer.33,34 Although 
VEGFR1 binds with high affinity to VEGF, VEGFR2 seems 
to mediate almost all aspects of the cellular responses to 
VEGF.35 It was proposed that VEGFR1 may work as a decoy 
receptor to facilitate the binding of VEGFR2 to VEGF.36 
VEGFR3 is widely expressed in malignant vascular tumors, 
but mostly in the capillaries and not in the solid tumors. 
Neuropilins have a high affinity to bind to certain isoforms 
of VEGF. VEGF can be regulated by many stimuli through 
a multitude of mechanisms, including various cytokines 
(eg, interleukin [IL]-4, IL-10, type I interferons), growth 
factors (eg, TGF-β; FGF), and hormones, as summarized 
by Xie et al.37 VEGF expression is also under the influence 
of various stresses such as oxidative stress,38 hypoxia,39 and 
glucose deficiency.40
The regulation of VEGF happens at the gene transcription, 
translation, and post-translation levels. In particular, regula-
tion at the transcription level has been extensively studied, 
and hypoxia-inducible factor-1, which is a master transcrip-
tion factor activated by hypoxia, and specific protein-1, 
which responds to various extracellular stimuli, have been 
demonstrated to play a fundamental role in the expression 
and secretion of VEGF.41
Architecturally different from the normal blood vessels, 
tumor blood vessels are a chaotic network of irregularly 
shaped, dilated, and tortuous vessels.16 The upregulation 
of VEGF, which results in endothelial cell sprouting, and 
the interaction between endothelial cells, pericytes, and 
stroma cells account for the main mechanisms of tumor 
angiogenesis.42–44 Blood vessel branching during angio-
genesis is a complex process that involves completion of a 
complex succession of events: 1) the presence of angiogenic 
factors such as VEGF and FGF induces degradation of the 
basement membrane, pericyte detachment, and loosening of 
the cell–cell junctional contacts to favor the navigation of 
delta-like 4-expressing tip cells; 2) with the guidance of tip 
cells, stalk cells proliferate, elongate, and form a lumen; and 
3) the establishment of new blood vessels, including vascular 
maintenance, basement membrane deposition, barrier forma-
tion, and pericyte maturation.45 In terms of molecular mecha-
nisms, the VEGF/VEGFR pathway can activate a variety of 
signaling pathways, including the phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K/AKT) and mitogen-activated 
protein kinases/extracellular signal-regulated kinases 
(MAPK/ERK, also known as Ras/Raf/MEK/ERK) pathways, 
to induce the proliferation, migration, and production of 
proteases, and vascular hyperpermeability.46
Angiogenesis is orchestrated by various activators and 
repressors. Besides the VEGF family, several other molecules 
or signaling pathways including PDGF, TGF-β, the FGF 
superfamily, epidermal growth factor (EGF), hepatocyte 
growth factor/scatter factor (HGF/SF), the tumor necrosis 
factor family (TNF), as well as the NOTCH/WNT signaling 
pathway, also significantly contribute to the development 
and maturation of vessels.45 Recent studies showed that 
vascular metabolism also plays an important role in regulat-
ing angiogenesis and is a viable target for manipulating the 
microvasculature.47 It remains to be further determined how 
these various components/signaling pathways functionally 
crosstalk to facilitate the tumor growth.
Strategies for targeting 
angiogenesis in tumors
The vital role of tumor angiogenesis in solid tumor holds much 
promise for designing efficacious treatments for cancers. 
Amongst the strategies for blocking angiogenesis, some drugs 
are designed to directly inhibit the proliferation or response 
of normal endothelial cells. Another important strategy aims 
to block the growth factors which mediate the cell signal-
ing pathways that stimulate angiogenesis.48  Antiangiogenic 
agents that are/were on clinical trials are mainly divided into 
several categories based on their  mechanisms: 1) drugs that 
directly inhibit endothelial cell proliferation and/or migra-
tion, such as thalidomide;49 2) agents that block angiogenesis 
signaling, such as bevacizumab;50 3) drugs that interfere with 
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degradation of the extracellular matrix, such as several MMP 
inhibitors; and 4) drugs that have multiple functions.51
To date, two important antiangiogenic approaches have 
achieved clinical development for cancer therapy (Figure 1). 
One is the development of targeted small-molecule protein–
tyrosine kinase inhibitors (TKIs), the other one is the gen-
eration of monoclonal antibodies. Both approaches have 
distinctive properties. Small-molecule agents can permeate 
through plasma membranes and disperse within the cells to 
reach their targets. In comparison, monoclonal antibodies 
are relatively large and generally cannot enter cells, so they 
are used to target unique cell-specific surface markers and 
redirect the targets to the immune system for resolution. 
Another major difference between TKIs and monoclonal 
antibodies is that the former can inhibit a wide range of 
tyrosine kinases and signaling pathways, but monoclonal 
antibodies are specific for one or two targets.52,53 Compared 
with the conventional cytotoxic chemotherapy, antiangio-
genic therapy is proposed to have several advantages: 1) 
it directly targets endothelial cells instead of working on 
tumor/epithelial cells; 2) it is not restricted to a specific 
histologic tumor entity; and 3) it is less likely to acquire 
drug resistance due to a lower chance of endothelial cells 
acquiring mutations.54
Rationale of targeting angiogenesis 
in esophageal cancer
The progression and aggressive behavior of esophageal 
cancer are associated with angiogenesis or VEGF/VEGFRs 
expression. BE is a precancerous condition for EAC, and 
patients with BE generally have a 30- to 50-fold greater risk 
of developing esophageal cancer.55 It had been reported that 
Barrett’s epithelium is strongly neovascularized.56 Another 
study based on 78 patients with Barrett’s adenocarcinoma 
found that VEGF is significantly correlated with vasculariza-
tion in both metaplasia and tumor.57 These studies indicate 
that angiogenesis can happen as early as the transition from 
metaplasia to neoplasia in the development of esophageal 
malignancies. Several individual studies also found upregu-
lation of VEGF in ESCC.58,59 Early lymphatic spread into 
local lymph nodes is a distinctive feature of esophageal 
cancer, and metastasis is one of the important reasons of 
high  mortality.60 Kitadai et al61 evaluated the expression of 
VEGF-C in 12 preoperative biopsies and 48 ESCC surgical 
Ras
Raf
MEK
ERK
MAPK
eNOS
Angiogenesis and vasculogenesis
AKT
PI3K
Endothelial cells
Growth factors
Tyrosine kinase inhibitor
Growth factor antibody
Growth factors
Receptor antibody
Tumor cells
mTOR
Figure 1 Diagram depicting the key antiangiogenic approaches and the mechanisms of action of antiangiogenic agents.
Notes: One of the approaches is the development of small molecules that inhibit tyrosine kinases. Another approach is the generation of monoclonal antibodies, which are 
engineered to target the growth factors or their receptors.
Abbreviations: MeK, mitogen-activated protein kinase kinase; MAPK, mitogen-activated protein kinase; eRK, extracellular signal-regulated kinase; Pi3K, phosphatidylinositol-
4,5-bisphosphate 3-kinase; AKT, protein kinase B; eNOS, endothelial nitric oxide synthase; mTOR, mammalian target of rapamycin.
Gastrointestinal Cancer: Targets and Therapy 2015:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
83
Targeting angiogenesis in esophageal cancer
specimens, and found that VEGF-C expression has signifi-
cant positive correlations with lymph node metastasis and 
distant  metastasis. The positive association between VEGF 
expression and poor prognosis in patients with esophageal 
cancer was summarized in a meta-analysis covering 1,543 
esophageal cancer patients with EAC or ESCC included 
in 19 studies published between 1997 and 2011.62 Another 
study comprising resected esophagus tissues in a cohort of 
55 ESCC and 13 EAC patients showed that the high expres-
sion level of VEGFR1, one of the two dominant receptors for 
VEGF, is associated with poorer outcomes.63 Furthermore, 
our own recent study demonstrated a significant positive cor-
relation between VEGFR2 expression and metastatic stage 
in a tissue array containing 86 cases of ESCC.25
Angiogenic factors circulating in the body fluid system, 
such as blood, can serve as useful biological markers. An 
analysis of serum VEGF-C and VEGF-D levels between 
esophageal cancer patients (110 with ESCC, 39 with EAC) 
and a healthy control group or patients with benign esophageal 
diseases showed that serum levels of VEGF-C and VEGF-D 
are associated with cancer stage and lymph node metastases.28 
In particular, a high serum VEGF-C level was found to be a 
significant predictive marker for poor outcomes for patients 
undergoing potentially curative esophagectomy.28 In a more 
recent study, a comparison of serum levels between 89 patients 
with esophageal cancer (63 ESCC and 26 EAC) with a control 
group showed that high serum VEGF-A is associated with 
tumor progression and unfavorable prognosis in patients.64 This 
study showed that VEGF is not only an intratumoral biomarker, 
but also a circulating marker for esophageal cancer, which is 
in concordance with other cancer types.65–67
Besides VEGF, other angiogenic-related factors have 
been reported to have clinical relevance. For example, over-
expression of FGF-2 messenger RNA in EAC and ESCC 
was observed to be associated with tumor recurrence and it 
reduced survival after the surgical resection of esophageal 
cancer.68 The expression of FGF-2, as well as EGF and HGF, 
was also evaluated in patients undergoing resection for GEJ 
adenocarcinoma, and the results confirmed that high levels 
of angiogenic factors are associated with unfavorable tumor 
characteristics and poorer overall survival.69 These studies 
collectively provide a rationale for antiangiogenic therapy 
in the treatment of esophageal cancer.
Antiangiogenic agents in the 
treatment of esophageal cancer
There is, as yet, no antiangiogenic agent approved for 
esophageal cancer. With recent advances in the develop-
ment of antiangiogenic compounds, some of the promising 
antiangiogenic agents have been tested in preclinical studies 
or clinical trials (usually in combination with chemora-
diotherapy or chemotherapy) (Tables 1 and 2). However, 
as will be described, most of the clinical studies involved 
subjects with advanced EAC or GEJ adenocarcinomas, so 
there is relatively little information of the efficacy of these 
drugs on ESCC.
Small-molecule therapeutics
Sunitinib is an orally administered multitargeted TKI that 
blocks VEGFRs, PDGF alpha and beta receptors (PDGFR), 
stem cell-factor receptor (Kit), and other receptor tyrosine 
kinases.70 It was first approved by the US Food and Drug 
Table 1 Summary of antiangiogenic small molecules used for the treatment of esophageal cancer
Name Targets References Clinical trial identifiers
Sunitinib veGFR, PDGFR, c-Kit 73, 74 NCT00702884, NCT00524186, NCT00891878, NCT00730353, NCT00400114
Sorafenib veGFR, PDGFR, FLT3 79, 97 NCT01262482, NCT00253370, NCT00917462, NCT01158287, NCT00619242
erlotinib eGFR 82, 83 NCT00045526, NCT01561014, NCT01013831, NCT00686114, NCT00524121, 
NCT00539617, NCT00442507, NCT00393068, NCT00030498, NCT00397384, 
NCT00566800, NCT00032123, NCT00591123, NCT02353936
Gefitinib eGFR 98, 99 NCT00258297, NCT00290719, NCT01243398, NCT00093652, NCT00100945, 
NCT00268346, NCT01291823, NCT00493025, NCT00215995, NCT00258323
Pazopanib veGFR1, veGFR2, veGFR3,  
PDGFR, FGFR, c-Kit
100 NCT00388076
Lapatinib HeR2/neu, eGFR 101, 102 NCT00239200, NCT01705340, NCT00313599, NCT01145404, NCT00259987, 
NCT01395537, NCT01123473, NCT00680901, NCT00447226
vandetanib veGFR2, eGFR, FLT4 73, 103 NCT00732745, NCT01183559
Brivanib veGFR1, veGFR2, veGFR3, 
FGF, FGFR
104 NCT00633789
Afatinib eGFR, HeR2 105 NCT01522768, NCT02353936, NCT02274012
Abbreviations: veGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor; c-Kit, tyrosine–protein kinase Kit; FLT3, Fms-related 
tyrosine kinase 3; EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; FLT4, Fms-related tyrosine kinase 4; FGF, fibroblast growth factor; 
HeR2, human epidermal growth factor receptor 2.
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Table 2 Summary of antiangiogenic monoclonal antibodies used for the treatment of esophageal cancer
Name Targets References Clinical trial identifiers
Bevacizumab veGF 83, 87 NCT01212822, NCT00636298, NCT00442507, NCT00393068, NCT00354679, NCT00570531, 
NCT02072720, NCT00217581, NCT00447330
Ramucirumab veGFR2 89 NCT01246960, NCT02314117, NCT02082210, NCT00917384, NCT02307812, NCT02065765
Cetuximab eGFR, MMP,  
iL-8
91, 92 NCT00578201, NCT01107639, NCT00096031, NCT00109850, NCT00445861, NCT00733889, 
NCT00636298, NCT00509561, NCT00655876, NCT01787006, NCT00544362, NCT00425425, 
NCT01034189, NCT00735345, NCT00381706, NCT00397904, NCT00165490, NCT00551759, 
NCT00130689, NCT00397384, NCT01904435, NCT00439608, NCT00815308, NCT01490749, 
NCT00827671, NCT00319735, NCT00183898, NCT02123381, NCT00430027, NCT01360086
Matuzumab eGFR 106–108 NCT00215644, NCT00113581
Panitumumab eGFR 109, 110 NCT01077999, NCT00578071, NCT00757172, NCT00004879, NCT01128387, NCT00101907, 
NCT00836277, NCT01307956, NCT01443065, NCT01262183, NCT01182610, NCT00667420, 
NCT01379807
Trastuzumab HeR2/neu 111 NCT02120911, NCT01196390, NCT01705340, NCT00004074, NCT01928290, NCT01522768, 
NCT01191697, NCT01774851, NCT02205463, NCT02305043, NCT01939275, NCT01359397, 
NCT01472029, NCT00005842
Abbreviations: veGF, vascular endothelial growth factor; veGFR2, vascular endothelial growth factor receptor 2; eGFR, epidermal growth factor receptor; MMP, matrix 
metalloproteinase; iL-8, interleukin-8; HeR2, human epidermal growth factor receptor 2.
Administration (FDA) in 2006 for the treatment of gastro-
intestinal stromal tumor and metastatic renal cell cancer.71 
With regard to esophageal cancer, a recent study showed that 
sunitinib inhibited autocrine VEGF signaling in  Barrett’s neo-
plastic cells and reduced xenograft tumor growth in a mouse 
model.72 Another preclinical study showed that although suni-
tinib could inhibit the proliferation of an esophageal cancer 
cell line, there was no synergistic effect with cisplatin.73 In a 
Phase II study of patients with advanced esophageal cancer 
(mostly adenocarcinoma), the combination of sunitinib plus 
paclitaxel did not provide survival benefits for the patients 
and had serious toxic effects.74
Sorafenib is a kinase inhibitor drug approved for the 
treatment of advanced renal cell carcinoma75 and advanced 
primary liver cancer.76 In 2013, it was also approved for 
the treatment of locally recurrent or metastatic, progressive 
differentiated thyroid carcinomas, which are refractory to 
radioactive iodine treatment.77 Besides inhibiting the VEGFR 
pathway, it can also block signaling from the PDGFR and 
Fms-related tyrosine kinase 3 (FLT3) pathways.78 Sorafenib 
was demonstrated to inhibit acid or bile acid-stimulated 
proliferation of Barrett’s esophageal cancer cells via the 
regulation of the MAPK pathway.79 In a Phase II study, the 
combination of sorafenib, docetaxel, and cisplatin had an 
encouraging efficacy profile in the treatment of metastatic 
or advanced gastric and GEJ adenocarcinoma with tolerable 
toxicity.80
Erlotinib is an EGF receptor (EGFR) inhibitor and it 
was approved by the US FDA in 2013 for use as a first-line 
treatment in patients with metastatic nonsmall cell lung 
cancer, whose tumors have EGFR exon 19 deletions or exon 
21 (L858R) substitution mutations.81 A recent study showed 
that the combined regimen of radiation and erlotinib has a 
beneficial outcome for elderly patients aged .70 years with 
esophageal cancer.82 However, in another Phase II study, 
the addition of bevacizumab and erlotinib to neoadjuvant 
chemoradiation did not demonstrate survival benefits in 
patients with localized esophageal cancer.83
Other synthetic small-molecule drugs, including gefitinib 
and pazopanib, are also under close investigation. Some 
anti-inflammatory drugs with antiangiogenic potential also 
look promising. For example, aspirin was demonstrated to 
greatly improve the 5-year survival of patients with T2N0M0 
ESCC.84
Large-molecule therapeutics
Bevacizumab, an anti-VEGF neutralizing antibody, was the 
first antiangiogenic agent to be approved by the US FDA 
in 2004 for the treatment of human colorectal cancer.85 
Bevacizumab functions by blocking the binding of VEGF to 
VEGFRs, thus normalizing the disorganized vasculature of 
tumors. A Phase II trial of combination therapy consisting of 
docetaxel, cisplatin, and fluorouracil with bevacizumab was 
reported to be tolerable and was found to notably improve 
the outcome in patients with metastatic gastroesophageal 
 adenocarcinoma.86 Another Phase II study combining beva-
cizumab, capecitabine, and oxaliplatin confirmed that beva-
cizumab can be given safely with chemotherapy in patients 
with metastatic gastroesophageal adenocarcinomas.87
Ramucirumab is a fully human immunoglobulin G1 
monoclonal antibody to VEGFR2. It works as a receptor 
antagonist by binding to VEGFR2, thus preventing the bind-
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ing of VEGF to VEGFR2. Ramucirumab was approved by 
the US FDA in 2014 to treat stomach cancer patients whose 
cancer could not be surgically removed or had metastasized.88 
A recent Phase III study involving 355 patients with advanced 
gastric or GEJ adenocarcinoma progressing after first-line 
chemotherapy showed that ramucirumab significantly 
extended the median overall survival time from 3.8 months 
to 5.2 months.89
Cetuximab is the first chimeric monoclonal anti-EGFR 
antibody. It can suppress the expression of VEGF, MMP, or 
IL-8, thus inhibiting angiogenesis.90 Promising results from 
a recent Phase II clinical trial showed that the administration 
of cetuximab combined with chemoradiotherapy improved 
the clinical response rate of patients with nonresectable, 
locally advanced ESCC.91 Moreover, results from another 
Phase II study suggest that the combination of cetuximab and 
radiation therapy may be better tolerated than preoperative 
chemotherapy and radiation therapy in patients with resect-
able esophageal cancers.92
Clinical trials involving several other monoclonal anti-
bodies, such as matuzumab and panitumumab, have also 
been conducted (Table 2). Besides monoclonal antibodies 
and receptor TKIs, a variety of other drugs have been shown 
to have one or more antiangiogenic properties. Aflibercept 
(VEGF-Trap), a soluble receptor chimeric protein, was engi-
neered to have high affinity for VEGF and thus functions as 
a decoy VEGF receptor.93 It was approved by the US FDA in 
2012 for the treatment of patients with metastatic colorectal 
cancer in combination with 5-fluorouracil, leucovorin, and 
irinotecan.94 Its efficacy in combination with FOLFOX in 
treating esophagogastric cancer is currently being investi-
gated in a Phase II trial (NLM identifier: NCT00215644).
Antiangiogenic therapy is a  
double-edged sword in esophageal 
cancer therapy
Although increasing preclinical and clinical evidence shows 
that antiangiogenic therapies have promising effects, the 
clinical use of antiangiogenic therapy seemed more complex 
than anticipated. To date, evidence of successful antian-
giogenic therapy in esophageal cancer is still lacking. The 
fact that a fraction of patients were refractory or developed 
resistance to anti-VEGF therapy through multiple mecha-
nisms in different cancer types remains a critical challenge 
for antiangiogenic therapy. The mechanisms of refractori-
ness to anti-VEGF therapy may, in part, be attributable to 
the fact that several other key mediators, besides the VEGF 
family, can switch on angiogenesis so that blocking VEGF 
alone is not  sufficient. Bergers and Hanahan94 referred to this 
phenomenon as “evasion of anti-angiogenic therapy” and 
proposed it as one of the important modes of resistance to 
antiangiogenic therapy. They also proposed “indifference 
to anti-angiogenic therapy” as another mode of resistance, 
which means that the angiogenic system supporting tumors 
in those patients resistant to antiangiogenic therapy may have 
already evolved before therapy.95 Another consideration is 
that in the dynamic tumor microenvironment, the persistent 
recruitment of BMDCs, such as CD11b+Gr1+ BMDCs, 
may revascularize tumors.23 Therefore, further studies are 
urgently called for to investigate the mechanisms of acquired 
resistance to antiangiogenic therapies, so as to facilitate the 
development of more advanced and effective strategies.
Conclusion and future perspectives
The incidence of esophageal cancer is increasing and the 
survival rate remains poor. As mentioned earlier, the progres-
sion of esophageal cancer is associated with  angiogenesis. 
Although antiangiogenic therapies showed promising results 
from preclinical and clinical studies, many aspects of angio-
genesis and antiangiogenic therapy remain to be further 
considered in order to overcome existing hurdles:
1. Angiogenesis is a multicellular and multistep process. 
There is still a lack of validated biomarkers to predict 
which patients may benefit from antiangiogenic drugs. 
Until now, only a few candidate biomarkers have been 
identified, but most of the studies were based on small 
patient cohorts.
2. Our understanding of the molecular mechanisms of the 
angiogenic switch is far from complete. Identification and 
deciphering of the roles/mechanisms of the molecules 
(including noncoding RNAs, which are currently under 
intensive investigation) involved in angiogenesis and 
vasculogenesis will facilitate the development of novel 
agents that can block the angiogenic switch.
3. Resistance remains one of the critical challenges for 
antiangiogenic therapy. Therefore, novel strategies to 
diminish the resistance to antiangiogenic therapies should 
be identified. The fact that antiangiogenesis agents are 
often used together with a diverse combination of con-
ventional chemotherapeutic drugs in the clinic needs to 
be taken into consideration when evaluating treatment 
response and the mechanism(s) of drug resistance.
4. The same angiogenic signaling pathway that works in 
the tumors also applies to various normal physiological 
vascular processes, such as wound healing and preg-
nancy. Antiangiogenic therapy inevitably introduces 
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undesirable or even serious side effects including fatigue, 
 hypertension, and neurotoxicity.96 The side effects of 
antiangiogenic therapy should be minimized, and the 
drug delivery and dosing should be further optimized.
In summary, to combat esophageal cancer, concerted 
effort by bench scientists, clinicians, and the pharmaceuti-
cal industry is paramount in developing safe and effective 
antiangiogenic strategies that will ultimately benefit cancer 
patients.
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